journal
https://read.qxmd.com/read/37734108/a-practical-guide-to-advanced-topical-drug-delivery-systems-in-dermatology
#1
JOURNAL ARTICLE
Andrei Metelitsa, Isabelle Delorme, Daniel O'Sullivan, Rami Zeinab, Mark Legault, Melinda Gooderham
Dermatological diseases such as atopic dermatitis, acne, and psoriasis result in significant morbidity and decreased quality of life. The first line of treatment for such diseases is often topical medications. While topical delivery allows active drug to be delivered directly to the target site, the skin is a virtually impermeable barrier that impedes delivery of large molecules. Thus, the formulation and delivery system are integral elements of topical medications. Patients also have preferences for the properties of topical formulations and these preferences can positively or negatively impact adherence...
September 2023: Skin Therapy Letter
https://read.qxmd.com/read/37734074/topical-roflumilast-for-plaque-psoriasis
#2
REVIEW
Ashley O'Toole, Melinda Gooderham
Roflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and tolerability. It is non-steroidal, administered once-daily, and highly potent, with a unique delivery formulation. It can be used on most body areas, including the sensitive intertriginous regions and face. Herein, we review the safety and efficacy of roflumilast 0.3% cream, as demonstrated in clinical trials...
September 2023: Skin Therapy Letter
https://read.qxmd.com/read/37440693/prevention-of-shingles-in-dermatology-patients-on-systemic-medications
#3
JOURNAL ARTICLE
Lyn Guenther
The lifetime risk for herpes zoster (HZ) of approximately 1 in 3 is increased with advancing age, a family history of HZ, diseases with altered immune function, immunosuppression, physical trauma and psychological stress. In dermatology, monotherapy with current biologics does not increase risk, however systemic steroids, Janus kinase inhibitors and combination biologic/conventional disease-modifying antirheumatics do. The recombinant zoster vaccine (RZV, Shingrix®), an adjuvanted non-live subunit vaccine against the glycoprotein E subunit of varicella zoster virus, is approved for prevention of HZ in adults ≥50 years of age, and adults ≥18 years of age who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression due to disease or treatment...
July 2023: Skin Therapy Letter
https://read.qxmd.com/read/37440610/daxibotulinumtoxina-lanm-daxxify%C3%A2-a-comprehensive-overview
#4
JOURNAL ARTICLE
Nicole Salame, Ariel E Eber, Jeffrey Dover
Botulinum toxin A (BoNTA) is produced by Clostridium botulinum and widely used for aesthetic indications requiring neuromuscular blockade. For dynamic facial lines, BoNTA is effective and safe, but also temporary, requiring repeat injections approximately every 3-4 months for maintenance of effects. There is a desire by both patients and providers for a longer-lasting neurotoxin to prevent periods of suboptimal correction. Approved by the US Food and Drug Administration (FDA) in September 2022, daxibotulinumtoxinA for injection (DAXI or Daxxify™) is the first long-lasting BoNTA formulated with a 150-kDa BoNTA (RTT150) and proprietary stabilizing excipient peptide (RTP004) in place of human serum albumin...
July 2023: Skin Therapy Letter
https://read.qxmd.com/read/37339609/utilization-of-topical-ruxolitinib-in-dermatology-a-review
#5
REVIEW
Nadia Kashetsky, Irina Turchin
As systemic administration of Janus kinase-inhibitors is associated with safety concerns, local alternatives, such as topical ruxolitinib, have been developed. This review summarizes utilization of topical ruxolitinib in dermatology. A literature search was performed of studies reporting topical use of ruxolitinib in dermatologic conditions. Twenty-four articles were included, representing 2618 patients. Results show improvement with topical ruxolitinib formulations in atopic dermatitis, vitiligo, psoriasis, and lichen planus...
May 2023: Skin Therapy Letter
https://read.qxmd.com/read/37339501/the-evolving-story-of-jak-inhibitors-for-treating-alopecia-areata-a-review-of-current-progress-and-future-directions
#6
REVIEW
Jeff Donovan
Oral Janus kinase (JAK) inhibitors now have a position as first-line agents for treating advanced alopecia areata. Oral JAK inhibitors are considerably more effective than topical JAK inhibitors, although topical agents may still have a valuable role for specific subgroups of patients. The US FDA approval of baricitinib in 2022 was an important milestone. Numerous JAK inhibitors are now being intensely studied for use in alopecia areata and several additional medications may also become approved in the near future...
May 2023: Skin Therapy Letter
https://read.qxmd.com/read/37054726/antibiotic-resistance-in-dermatology-part-2-combating-resistance
#7
JOURNAL ARTICLE
Austinn C Miller, Susuana Adjei, Laurie A Temiz, Sonali Batta, Stephen K Tyring
Virtually any antibiotic can be used in dermatology given the broad range of conditions treated. With the widespread use of antibiotics and the rapid emergence of resistant organisms, it is important to understand how dermatologists can combat this issue.
March 2023: Skin Therapy Letter
https://read.qxmd.com/read/37054720/chlormethine-gel-for-the-treatment-of-mycosis-fungoides-cutaneous-t-cell-lymphoma-in-canada
#8
JOURNAL ARTICLE
Robert Gniadecki, Emilia Paron
Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), representing almost 50% of all lymphomas arising in the skin. There is an unmet need in the treatment of MF in Canada, as current available therapies for early-stage MF are limited, without topical agents previously indicated. Chlormethine gel is a topical antineoplastic agent with phase II clinical trial and real-world data demonstrating safety and efficacy as a treatment option for adults with MF. Skin-related side effects such as dermatitis can be managed through appropriate strategies...
March 2023: Skin Therapy Letter
https://read.qxmd.com/read/36657435/antibiotic-resistance-in-dermatology-part-1-mechanisms-of-resistance
#9
JOURNAL ARTICLE
Austinn C. Miller, Susuana Adjei, Laurie A. Temiz, Stephen K. Tyring
Virtually any antibiotic can be used in dermatology given the broad range of conditions treated. With the widespread use of antibiotics and the rapid emergence of resistant organisms, it is important to understand the mechanisms at play that contribute to resistance.
January 2023: Skin Therapy Letter
https://read.qxmd.com/read/36657434/tralokinumab-for-moderate-to-severe-atopic-dermatitis-in-adults
#10
REVIEW
Abrahim Abduelmula, Brian D Rankin, Asfandyar Mufti, Jensen Yeung, Vimal H Prajapati
Atopic dermatitis (AD) is a common, chronic, recurrent, immune-mediated inflammatory skin disease. Targeted treatment options remain limited. Tralokinumab (Adtralza®) is a promising, new systemic therapy that inhibits interleukin-13. It was recently approved by Health Canada and the US FDA for the treatment of moderate-to-severe AD in adults and may be used alone or with topical corticosteroids. Herein, we review the efficacy and safety of tralokinumab in adults, as demonstrated in clinical trials.
January 2023: Skin Therapy Letter
https://read.qxmd.com/read/36469561/acne-scars-an-update-on-management
#11
JOURNAL ARTICLE
Abdulhadi Jfri, Ali Alajmi, Mohammad Alazemi, Malika A Ladha
Acne vulgaris is a troubling skin disease known to have both physiologic and psychological effects on patients. Acne scars, a frequent complication, can further impact patients' quality of life. Scars result from an impairment in the healing process. Acne scars can be categorized as follows: atrophic scars (including ice pick, rolling, boxcar subtypes) and trophic (including hypertrophic and keloid scars), the latter being less common. Though various treatment approaches have been suggested, there is a lack of high-quality evidence on effective, type-specific acne scar approaches...
November 2022: Skin Therapy Letter
https://read.qxmd.com/read/36469536/selective-tyk2-inhibition-in-the-treatment-of-moderate-to-severe-chronic-plaque-psoriasis
#12
JOURNAL ARTICLE
Melinda J Gooderham, H Chih-Ho Hong, Ivan V Litvinov
Moderate to severe chronic plaque psoriasis may be difficult to control using current therapies, which has led to development of a novel class of therapy, selective tyrosine kinase 2 (TYK2) inhibitors, to address this unmet need. Oral deucravacitinib is a first-inclass selective TYK2 inhibitor, which has shown efficacy in moderate to severe chronic plaque psoriasis from two phase III pivotal trials (POETYK PSO-1 and PSO-2), whereby response rates were significantly higher with deucravacitinib vs. placebo or apremilast for Psoriasis Area Severity Index (PASI) 75 and static Physician's Global Assessment (sPGA) 0/1...
November 2022: Skin Therapy Letter
https://read.qxmd.com/read/36469487/toxic-epidermal-necrolysis-a-review-of-past-and-present-therapeutic-approaches
#13
REVIEW
Neha Singh, Mariana Phillips
Toxic epidermal necrolysis (TEN) is an immune mediated, severe cutaneous adverse drug reaction characterized by epidermal detachment affecting greater than 30% body surface area. The mortality rate of TEN exceeds 20% and is usually caused by infection and respiratory compromise. Withdrawal of the causative drug, supportive care, and adjuvant therapy improve prognosis. Over the past decade, randomized controlled trials and meta-analyses have supported a role for cyclosporine, tumor necrosis factor alpha inhibitors, and combination therapy with intravenous immune globulin and corticosteroids...
September 2022: Skin Therapy Letter
https://read.qxmd.com/read/36469458/extracorporeal-photopheresis-and-its-use-in-clinical-dermatology-in-canada
#14
REVIEW
François Lagacé, Elena Netchiporouk, Irina Turchin, Wayne Gulliver, Jan Dutz, Mark G Kirchhof, Popradi Popradi, Robert Gniadecki, Charles Lynde, Ivan V Litvinov
Extracorporeal photopheresis (ECP) is an immunomodulatory therapy that has been used for over 35 years to treat numerous conditions. ECP was initially approved by the US FDA in 1988 for the treatment of Sézary syndrome, a leukemic form of cutaneous T-cell lymphoma (CTCL). Although CTCL remains the only FDA-approved indication, ECP has since been used off-label for numerous other conditions, including graft-versus-host disease (GvHD), systemic sclerosis, autoimmune bullous dermatoses, Crohn's disease, and prevention of solid organ transplant rejection...
September 2022: Skin Therapy Letter
https://read.qxmd.com/read/35857917/tirbanibulin-for-the-treatment-of-actinic-keratosis-a-review
#15
REVIEW
Austinn C Miller, Susuana Adjei, Laurie A Temiz, Stephen K Tyring
Actinic keratosis (AK) is a common precancerous condition found on chronically sun-damaged skin, particularly on the face, scalp, arms, and legs. Early and effective treatment of AKs is important to prevent progression to squamous cell carcinoma. Many topical treatments for AKs are often limited because of poor tolerability, prolonged treatment duration, and reduced adherence. Tirbanibulin 1% ointment, a new topical field therapy for AKs, reduces these issues. It requires a consecutive 5-day application period and is effective, demonstrating complete (100%) clearance of AK lesions in 49% of patients, partial (>75%) clearance in 72%, and a median reduction in lesion count of 87...
July 2022: Skin Therapy Letter
https://read.qxmd.com/read/35857858/tazarotene-lotion-0-045-for-the-treatment-of-acne
#16
JOURNAL ARTICLE
Catherine Zip
Topical retinoids are recommended as first line therapy for the treatment of acne. Despite this recommendation, topical retinoids are underutilized, in part because of their tendency to cause cutaneous irritation. Tazarotene 0.045% lotion was developed using polymeric emulsion technology to provide an effective, well tolerated topical retinoid for the treatment of acne.
July 2022: Skin Therapy Letter
https://read.qxmd.com/read/35533371/sarecycline-a-narrow-spectrum-antibiotic
#17
JOURNAL ARTICLE
Susuana Adjei, Austinn C Miller, Laurie A Temiz, Stephen K Tyring
Tetracycline-class drugs have been used for first-line treatment of moderate-to-severe acne and rosacea for decades. Recently, a new third generation tetracycline, sarecycline, was US FDA-approved for the treatment of moderate-to-severe acne. This narrow-spectrum tetracycline-derived antibiotic has been shown to be effective with an improved safety profile.
May 2022: Skin Therapy Letter
https://read.qxmd.com/read/35533304/halobetasol-propionate-0-01-lotion-for-plaque-psoriasis-and-corticosteroid-responsive-dermatoses
#18
JOURNAL ARTICLE
Abrahim Abduelmula, Brian D Rankin, Ronald Vender, Jensen Yeung, Alim R Devani, Vimal H Prajapati
A novel topical corticosteroid, halobetasol propionate (HP) 0.01% lotion (Bryhali™), has recently been introduced for the treatment of plaque psoriasis and corticosteroid-responsive dermatoses in adults. Once daily application of HP 0.01% lotion is indicated for use up to 8 weeks. Treatment success for plaque psoriasis in the pivotal phase 3 clinical trials (defined as an Investigator Global Assessment [IGA] of clear/almost clear [IGA 0/1] with ≥2-grade improvement from baseline) occurred in over one-third of patients by week 8...
May 2022: Skin Therapy Letter
https://read.qxmd.com/read/35385631/transition-of-topical-therapy-formulation-in-psoriasis-insights-from-a-canadian-practice-reflective
#19
JOURNAL ARTICLE
David N Adam, Sonya J Abdulla, Patrick Fleming, Melinda J Gooderham, John Ashkenas, Clinton B McCracken
Patient preferences for psoriasis treatment may affect treatment adherence and disease control; changing topical formulation may improve adherence and patient acceptance of treatment. This study explored dermatologists' reasons for transitioning psoriasis patients from an ointment or gel (Dovobet®) formulation to an aerosol foam (Enstilar®) formulation of calcipotriol and betamethasone dipropionate (Cal/BD), and to assess the success of this transition. Medical records of 81 Canadian patients from 9 dermatologists were retrospectively reviewed for symptoms affecting quality of life, reasons for transitioning treatment, and whether transition was successful...
March 2022: Skin Therapy Letter
https://read.qxmd.com/read/35385630/plerixafor-on-a-whim-promise-or-fantasy-of-a-new-cxcr4-inhibitor-for-this-rare-but-important-syndrome
#20
REVIEW
Nickoo Merati, Sriraam Sivachandran, Abdulhadi Jfri, Moshe Ben-Shoshan, Donald C Vinh, Gizelle Popradi, Ivan V Litvinov
Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) is a primary immunodeficiency syndrome. Patients with WHIM syndrome are more susceptible to human papillomavirus (HPV) infections and commonly present to a dermatologist with recalcitrant to treatment warts. Other cardinal features of WHIM syndrome include recurrent sinopulmonary bacterial infections, neutropenia/lymphopenia, low levels of immunoglobulins (IgG, IgA, IgM) and myelokathexis. Research demonstrated that truncating gain-of-function mutations of the C-X-C chemokine receptor type 4 gene (CXCR4) are responsible for this disease...
March 2022: Skin Therapy Letter
journal
journal
34395
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.